Discovery of VU6008677: A Structurally Distinct Tricyclic M Positive Allosteric Modulator with Improved CYP450 Profile
Authors
Capstick
RA
Rory A
,
Bollinger
SR
Sean R
,
Engers
JL
Julie L
,
Long
MF
Madeline F
,
Chang
S
Sichen
,
Luscombe
VB
Vincent B
,
Rodriguez
AL
Alice L
,
Niswender
CM
Colleen M
,
Bridges
TM
Thomas M
,
Boutaud
O
Olivier
,
Conn
PJ
P Jeffrey
,
Engers
DW
Darren W
,
Lindsley
CW
Craig W
,
Temple
KJ
Kayla J
.
ACS medicinal chemistry letters. 2024 07 03; 15(8).
1358-1366
ACS medicinal chemistry letters. 2024 07 03; 15(8).
1358-1366
Abstract
This Letter details our efforts to develop novel tricyclic muscarinic acetylcholine receptor subtype 4 (M) positive allosteric modulator (PAM) scaffolds with improved pharmacological properties. This endeavor involved a “tie-back” strategy to replace the 3-amino-5-chloro-4,6-dimethylthieno[2,3-]pyridine-2-carboxamide core, which led to the discovery of two novel tricyclic cores: an 8-chloro-9-methylpyrido[3′,2′:4,5]thieno[3,2-]pyrimidin-4-amine core and 8-chloro-7,9-dimethylpyrido[3′,2′:4,5]furo[3,2-]pyrimidin-4-amine core. Both tricyclic cores displayed low nanomolar potency against human M and greatly reduced cytochrome P450 inhibition when compared with parent compound .